DrugPatentWatch Database Preview
Wellstat Therap Company Profile
What is the competitive landscape for WELLSTAT THERAP, and what generic alternatives to WELLSTAT THERAP drugs are available?
WELLSTAT THERAP has two approved drugs.
There are two US patents protecting WELLSTAT THERAP drugs.
Summary for Wellstat Therap
| US Patents: | 2 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Wellstat Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | 6,258,795 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | 7,776,838 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Wellstat Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | 5,968,914 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for Wellstat Therap
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,060,459 | Enhancing blood cell count with oxypurine nucleosides | ➤ Try a Free Trial |
| 6,329,350 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | ➤ Try a Free Trial |
| 6,103,701 | Method for enhancing hematopoiesis with acyl deoxyribonucleosides | ➤ Try a Free Trial |
| 6,306,834 | Acyl deoxyribonucleoside derivatives and uses thereof | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Wellstat Therap Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Australia | 7881398 | ➤ Try a Free Trial |
| Israel | 102407 | ➤ Try a Free Trial |
| Austria | 320813 | ➤ Try a Free Trial |
| Australia | 6081294 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Wellstat Therap Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0889 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427 |
| 2017 00036 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
